Can You Prove You Have the Right Molecule?

Follow the step-by step the pathway to develop your biotherapeutic peptide

From impurity characterization to regulatory compliance, explore how robust LC and LC-MS workflows help bring biotherapeutic peptides to market faster while ensuring product quality and safety.

Join our webinar series which addresses each stage and hear expert discussions on how analytical solutions can help accelerate time to market and speed up regulatory approvals.

Step 1: Can You Prove You Have the Right Molecule?

Confirm the Identity of Your GLP-1 Therapeutic

As GLP-1 pipelines continue to expand, comprehensive peptide characterization has become a critical requirement for development and regulatory success. Understanding the sequence, structure, and integrity of your molecule is the foundation for every subsequent development decision.

In this session, discover how advanced LC-MS workflows provide the structural insight needed to confidently confirm peptide identity, detect modifications, and generate the robust analytical evidence regulators increasingly expect.

Why attend?

• Confirm peptide identity and sequence integrity with confidence
• Detect unexpected modifications and structural variants early
• Understand the growing importance of orthogonal characterization approaches
• Generate analytical data to support future regulatory submissions

Key takeaway

Learn how to confidently demonstrate that your GLP-1 therapeutic is the molecule you intended to develop.

Meet the Expert(s)

Hear from Waters scientists and market experts who work with pharmaceutical manufacturers every day to solve analytical challenges across the entire GLP-1 development lifecycle, from molecule characterization and purification through to QC and regulatory readiness.

Speaker: Isabel Riba (Principal Sales Applications Chemist, Waters Corporation)

is a Principal Sales Applications Chemist at Waters Corporation with extensive experience in LC and LC-MS technologies for the characterization of complex biomolecules. She works closely with pharmaceutical and biotechnology organizations to develop analytical strategies that support peptide characterization, structural analysis, and regulatory submissions. In this session, Isabel will discuss how advanced analytical approaches can help confidently confirm the identity and integrity of GLP-1 therapeutics.

 

Speaker: Antonia Wierzbicki (Principal MS Market Development Manager, EMEA, Waters Corporation)

Antonia Wierzbicki is Principal Market Development Manager for Pharma in EMEA at Waters Corporation. She leads strategic initiatives focused on therapeutic peptides, GLP-1 receptor agonists, DMPK, and bioanalysis. Working closely with pharmaceutical innovators, CDMOs, and peptide manufacturers, Antonia helps organizations address analytical challenges throughout development and manufacturing. In this session, she will explore purification strategies that enable improved impurity control, greater analytical confidence, and faster GLP-1 development.